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Abstract
Objectives: This study aims to determine the efficacy and safety of soy isoflavones in controlling the symptoms
and signs of lower urinary tract symptoms due to benign prostate hyperplasia (BPH).
Design: This was a prospective, randomized, double-blind, placebo-controlled pilot study.
Setting: This trial was conducted at two hospitals in Hong Kong between May 2006 and September 2007.
Participants: One hundred and seventy-six (176) participants diagnosed with BPH were recruited from out-
patient clinics. Participants with lower urinary tract symptoms were recruited through newspaper and radio
interviews, posters placed at government outpatient clinics, and a public seminar offered by the investigators.
Interventions: Participants were randomly assigned to either intervention (40mg of isoflavones daily from
Soylife 40) or placebo groups in a double-blind fashion.
Main outcome measures: The primary outcome parameter of peak urine flow rate and the second outcome
parameters of postresidual urine volume, lower urinary tract symptoms, testosterone, prostate-specific antigen,
quality of life, diet, and safety profile (liver and renal function) were collected. All parameters were assessed at
baseline, 6 months, and 12 months in a 12-month study period except testosterone, prostate-specific antigen, and
safety profile, which were assessed at baseline and at 12 months.
Results: The peak urine flow rate (Qmax), postresidual urine volume, International Prostate Symptoms Scores
(IPSS), and 36-Item Short Form Health Survey (SF-36) significantly improved from baseline to the 12th month
within both groups. However, when compared between groups, Qmax ( p = 0.055) and incomplete emptying
subscore in IPSS ( p = 0.05) were marginally/statistically different between the two groups from the 6th to the
12th months, in addition to the general health domain of SF-36 from the baseline to 12th month ( p = 0.02) and
from the 6th month to the 12th month ( p = 0.055). Isoflavones were generally safe and well tolerated.
Conclusions: This randomized control pilot study showed only slight superiority of isoflavones over placebo
over 12 months with otherwise surprising beneficial effects in both groups. Tolerability of isoflavones was
excellent; thus it has laid foundations for further studies of isoflavones in BPH with focus on dosage and possible
specificity of the effect.
Introduction
Phytotherapy, or the use of plants and herbs for me-dicinal purposes, has been popular in Europe for the
treatment of lower urinary tract symptoms (LUTS) or benign
prostate hyperplasia (BPH), which is defined as an increase in
the size of the prostate for many years.1,2 In Italy, nearly half
the medications for BPH are phytotherapeutic agents.3 In
Germany and Austria, phytotherapeutic medications are the
first-line treatment for mild-to-moderate urinary obstructive
symptoms and represent 90% of all drugs prescribed for
BPH.3 In North America, at least 30% of men diagnosed with
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prostate disease use some complementary and alternative
medical (CAM) therapy.4,5 Alternative medicines are also
widely accepted in Hong Kong, with increasing numbers of
patients expecting to explore nutritional and complementary
therapies with Traditional Chinese Medicine particularly
popular among the locals: 83.7% of the Hong Kong general
population had consulted a Chinese therapist in the previous
year.6
Among 30 phytotherapeutic compounds available for the
treatment of BPH, the extracts of Serenoa repens (American
saw palmetto) and Pygeum africanum (African prune tree),
b-sitosterol (the extract of South Africa star grass), and Cer-
nilton (the extract of rye-grass pollen Secale cereale) are
commonly used. Systematic reviews of randomized con-
trolled trials using these compounds have demonstrated
significant clinical effects of varying degrees in reduction in
International Prostate Symptoms Scores (IPSS), peak urine
flow rate, and/or residual volume, some comparable to
a-reductase inhibitors but with fewer undesired effects and
at lower costs. They are also generally well tolerated when
compared to other prescription medicines.7–10 Nonetheless,
all reviews warn that their long-term effectiveness and abil-
ity to prevent BPH complications are not known.
The two forms of isoflavones, aglycone and glucoside,
are commonly used dietary supplements among patients
with BPH.11 These are polyphonic compounds found pre-
dominantly in soy food and red clover. Numerous studies
have shown that isoflavones have effects on glandular
epithelium in the prostate involving 5-a-reductase in-
hibition and uridine 5-diphospho-glucuronsyltransferase
(UDP-glucuronsyltransferase, UGT) activation, and also
have effects on stromal cell in the prostate including
17-phydroxysteroid dehydrogenase inhibition, aromatase in-
hibition, and estrogen-receptor antagonism.12–16 Some epide-
miological studies also link a low incidence of BPH with a diet
rich in isoflavones; for example, Japanese males who had a
lower incidence of BPH had high levels of isoflavone phy-
toestrogens in plasma and urinary excretion,17 and males from
Hong Kong had higher levels of daidzein and a metabolite of
daidzein, equol, in their plasma and prostate fluid compared
to British and Portuguese men.18 At the same time, when
males from low BPH incident countries migrated to high in-
cident counties and adopted local dietary customs, their risk
of BPH rose significantly.19 One study demonstrated a corre-
lation between high consumption of soy milk and a reduced
risk of BPH among Seventh Day Adventist men.20
Despite the good evidence in both preclinical and epide-
miologic studies, no randomized controlled trial has yet been
reported to assess the effectiveness of isoflavones among men
with benign BPH (i.e., those who chose not to have any active
interventions for mild symptoms, or even moderate-to-severe
symptoms without complications). The aims of this trial were
to determine the safety and efficacy of soy isoflavones in
controlling symptoms among this group of patients.
The primary outcome was
 The uroflowmetry with measuring the peak urine flow
rate (Qmax).
The secondary outcomes were:
 The postresidual urine volume (PVR)
 The LUTS
 The quality of life using IPSS
 Any severe adverse events as a result of treatment.
Materials and Methods
This study was a randomized, double-blinded, placebo-
controlled prospective pilot trial. This trial was conducted at
Prince of Wales and Shatin Hospitals in Hong Kong between
May 2006 and September 2007. Participants with watchful
waiting BPH, which is defined as mild LUT symptoms
(Qmax < 15mL and PVR ‡ 150mL)21 without complication
and medical management required were recruited through
newspaper and radio interviews, posters placed at govern-
ment outpatient clinics, and a public seminar offered by the
investigators. The inclusion criteria were the following:
 Chinese resident living in Hong Kong
 Age between 45 and 85 years
 Diagnosed BPH with Qmax < 15mL/sec22 and a PVR
‡ 150mL22
 IPSS > 823
 Not on any concurrent or alternative medications for
BPH or a-1 inhibitor (e.g., doxazosin for cardiac reasons)
 Mentally capable of giving informed written consent
and willing to comply with study protocol.
A subject would be excluded for the following:
 Concurrent treatment for unstable chronic diseases in-
cluding unstable angina, poorly controlled diabetes
mellitus (hemoglobin A1c > 7.5%), less than 3 months
post–myocardial infarction or frequent exacerbation of
chronic obstructive airway diseases
 Known to have prostate cancer
 Known kidney and/or liver failure
 Urinary symptoms due to known causes other than
BPH including neurogenic bladder, urinary tract infec-
tion, bladder cancer, bladder stone, urethral stricture;
 Previous history of prostatic surgery
 Illiterate or having difficulty in filling in a patient diary;
 Known hypersensitivity to soy.
Based on the efficacy of finasteride from a previous clinical
trial, a minimal difference of 2mL/sec in Qmax between two
groups was used to estimate the sample size in this study.22
Eighty-eight (88) subjects in each groupwere required to achieve
80% power at 0.05 significance level, assuming a 10% dropout
rate as per a previous alternative medicine study in BPH.24
Randomization was generated using a computer random
number table in blocks of four by the pharmacist ( JY) who
was also responsible for the preparation of the drugs, but
unknown to any of the doctors or research staff. The studied
drug, containing 40mg aglycone-equivalent isoflavones in
each capsule, was prepared from Soylife 40 (Acatris, The
Netherlands). The placebo used starch and was the same
color, size, and shape capsule as the studied drug. Few
guidelines are available on optimal dose and length of
treatment for patients with LUT,25 but Japanese males are
estimated to consume 20mg of isoflavones per day,26 and
Kumar et al. used 60mg of isoflavones in a randomized
controlled trial with significant reduction in prostate-specific
antigen (PSA).27 Hence, 40mg of isoflavones was suggested
for this study with regard to the tolerability consideration.
All subjects were followed up every 3 months over a
12-month period. In each visit, the subjects completed
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questionnaires on demographics, IPSS, and SF-36 that had
previously been translated and validated in Chinese.28 A
well-trained male nurse who was blinded to the study group
allocation would then perform an uroflowmetry measuring
Qmax, an ultrasound scan of the bladder for PVR, and uri-
nalysis on the urine sample. Blood was taken for total tes-
tosterone, liver function test, and full blood count at baseline,
6 months, and 12 months, and for PSA and renal function at
baseline and 12 months.
Once enrolled, each participant was asked to record their
dietary information in a patient diary for 1 week immedi-
ately preceding the clinic visit to allow comparison of soy
consumption. Assessment of dietary intake was made using
the 7-day diet recall (7DDR).29 Briefly, the 7DDR was a
validated, self-administrated instrument designed to mea-
sure energy and macronutrient intake during the previous 7
days. Questions on portion size and number of times con-
sumed were asked for 10 soy-food items. Questionnaires
data were converted to nutrient data by using the Nutrition
Data System database as the unit of grams/day. Dietary food
intake of soy isoflavones was compared between two groups
at each visit. The content of soy food such as one bowl of tofu
or a half bottle of soy milk was transformed into grams in
order to be standardized. Participants were also asked to
record any adverse reactions noted or concurrent medica-
tions (including rescue medications) in the case-report form.
These were reviewed by a doctor at each visit when physical
examination and compliance check was conducted.
This study was approved by the joint Clinical Research
Ethics Committee of the Chinese University of Hong Kong
and Hospital Authority, Hong Kong. Written informed
consent was obtained from all subjects, and they were able to
terminate the participation of the trial at any stage. They
were also encouraged to contact the research team for any
inquiries during and after the trial. Any subject not returning
as scheduled was contacted by telephone to determine his
reasons for defaulting or to rearrange another appointment
within 7 days. Failure to attend the rescheduled visit was
regarded as withdrawal from the study.
Data entry and management was performed using SPSS
11.0. Due to the pilot character of the trial, evaluation was
done only with descriptive statistics. Baseline comparisons
for the Qmax, PVR, IPSS, SF-36, PSA, and testosterone levels
between the isoflavones group and the placebo group were
first performed by using Wilcoxon rank sum test. The mean
differences at 12 months between the two groups were
compared by using independent t tests for normal distribu-
tion variables and Mann–Whitney for non-normal distribu-
tion variables. The change during the intervention between
two groups was compared by using repeated the analysis of
covariance test. Normality checking for all outcome mea-
sures was performed, and the power was also computed for
each comparative analysis. All the analyses were based on
intention-to-treat by using the ‘‘last observation carried for-
ward’’ method.
Results
Following recruitment, 551 patients were evaluated for
potential enrollment. Three hundred and seventy-five (375)
participants did not meet the inclusion and exclusion criteria
or refused to participate in the trial: 210 patients had Qmax
larger than 15mL/sec; 130 postresidual volume smaller than
150mL; and 35 refused to participate in the study due to the
FIG. 1. Flow chart showing the ran-
domization, participation, and comple-
tion of the study.
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frequent study visits required. One hundred and seventy-six
(176) patientswhomet the inclusion and exclusion criteriawere
randomly assigned to two groups. After 1 year of follow-up, a
total of 30 patients hadwithdrawn from the study, of whom 16
were from the treatment group. The randomization and rea-
sons for withdrawal are detailed in Figure 1.
The demographic characteristics of the participants are
presented in Table 1. The mean age of the patients in the
isoflavones group was 65.0 – 9.4 years, whereas the mean age
of the placebo group was 65.1 – 9.2 years. The mean weight,
height, and blood pressure appeared to be similar in both
groups. Similar proportions of co-morbidity were also found
between the two groups: 85.2% (75/88) in the isoflavones
group and 81.8% (72/88) in the placebo group. In addition,
the means of IPSS score in the isoflavones and placebos
groups were 20.2 – 6.4, and 19.5 – 7.0, respectively ( p = 0.4)
(Table 2). The means of Qmax were 10.0 – 2.5mL/sec and
10.3 – 3.0mL/sec ( p= 0.3), whereas those of PVR were
125.9 – 132.1mL and 107.5– 77.5mL in the isoflavones and
placebo groups, respectively ( p= 0.8). No statistical differ-
ence in each domain of SF-36 scores was observed between
the two groups. There was also no significant difference in
serum PSA and testosterone levels at the beginning of the
trial. (PSA 1.7 – 0.9 ng/mL in the isoflavones group versus
1.6 – 0.8 ng/mL in the placebo group [p = 0.5]; the serum
testosterone level was 15.9 – 5.0 ng/mL in the isoflavones
group versus 15.8 – 6.4 ng/mL in the placebo group [p= 0.5]).
Therefore, both groups were rather comparable at baseline.
At the end of the year, Qmax increased and PVR de-
creased significantly within both groups ( p < 0.001) (Table 3).
The mean changes of Qmax and PVR were 1.7 – 3.8mL/sec
and 49.0 – 121.4mL in the isoflavones group, and 1.3 –
3.4mL/sec and 40.0 – 76.0mL in the placebo group, respec-
tively. During the second half of the intervention (i.e., from
the 6th month to the 12th month), the change in Qmax was
marginally different between the two groups ( p= 0.055) but
no significant change from the baseline to 12th month was
found between the two groups ( p= 0.64). There was no sig-
nificant change of PVR from the baseline to the 6th month
( p = 0.79) or from the 6th to the 12th month ( p= 0.18) be-
tween the two groups. The change trends of Qmax and PVR
from the baseline to the 12th month ( p = 0.77 and p= 0.13,
respectively) or from the 6th to the 12th month ( p = 0.65 and
p= 0.16, respectively) were not statistically significant (Figs. 2
and 3).
Similarly, the overall IPSS (p < 0.001) and the great ma-
jority of IPSS items decreased significantly from the baseline
to the 12th month in both groups. The change of incomplete
emptying scores between the two groups from the 6th to the
12th month was found to be significantly different ( p= 0.05).
The change trend between the two groups from baseline to
the 12th month ( p= 0.75) and from the 6th to the 12th month
( p = 0.72) was not significantly different with the exception of
the ‘‘incomplete emptying’’ score ( p = 0.05). However, the
changes of the general health domain of SF-36 between the
two groups from the baseline to the 12th month ( p = 0.02)
and from the 6th month to the 12th month ( p = 0.055) were
(marginally) significantly improved (Table 3).
Since the dietary intake of soy products may affect the
result of this trial, participants from both the intervention
and control groups were asked to record 7-day food intake in
the patient diary every 3 months during the study period for
comparison of the soy consumption. There was no significant
difference in soy consumption in both groups at each visit
(Table 4). However, both groups had an obvious decrease of
soy food intake in their daily diet. Because there was no
difference in dietary soy isoflavones intake between the two
groups at each stage of the trial and adjusted analysis by
controlling the soy food intake at each stage of the trial had
not shown the significantly different results, the interference
effect of soy food intake on the result was disregarded.
The proportion of patients experiencing any ad-
verse events was not significantly different between
Table 1. Demographics and Clinical Data
of Two Groups
Placebo group
(n = 88)
Isoflavones group
(n = 88)
Mean –SD Mean –SD
Age (y) 65.1 – 9.2 65.0 – 9.4
Weight (kg) 62.8 – 9.8 66.4 – 10.3
Height (m) 1.7 – 0.1 1.7 – 0.1
Systolic BP (mm Hg) 127.9– 12.0 129.9– 15.8
Diastolic BP (mm Hg) 77.0 – 8.4 79.1 – 9.5
Comorbidity:
Chronic disease 66 (75%) 72 (81.2%)
Cardiovascular disease 28 (31.8%) 32 (36.4%)
Hypertension 11 (12.5%) 7 (8.0%)
Diabetes 3 (3.4%) 11 (12.5%)
Angina 21 (23.9%) 17 (19.3%)
Abnormal liver function 2 (2.3%) 4 (4.5%)
Abnormal renal function 1 (1.1%) 1 (1.1%)
Acute disease 6 (6.8%) 3 (3.4%)
SD, standard deviation; BP, blood pressure.
Table 2. Baseline Comparisons Between
the Intervention and Placebo Groups
Placebo
group
(n = 88)
Isoflavones
group
(n = 88)
Mann–
Whitney
test
Mean –SD Mean – SD p-Value
IPSS 19.5 – 7.0 20.2 – 6.4 0.4
Peak urine flow
(mL/sec)
10.3 – 3.03 10.0 – 2.5 0.3
Residual urine
volume (mL)
107.5– 77.5 125.9– 132.1 0.8
QOL SF-36
Physical functioning 26.3 – 3.4 26.7 – 3.3 0.3
Role-physical 6.5 – 1.6 6.5 – 1.6 1.0
Body pain 9.0 – 2.5 9.2 – 2.3 0.7
General health 15.6 – 2.1 15.6 – 1.7 0.2
Vitality 16.1 – 2.5 15.6 – 1.7 0.2
Social functioning 8.1 – 1.8 8.4 – 1.4 0.3
Role-emotional 4.9 – 1.1 4.9 – 1.2 0.6
Mental health 21.3 – 3.3 21.5 – 3.1 0.5
PSA level (ng/mL) 1.6 – 0.8 1.7 – 0.9 0.5
Testosterone level
(lg/mL)
15.8 – 6.4 15.9 – 5.0 0.5
SD, standard deviation; IPSS, International Prostate Symptoms
Scores; QOL SF-36, Quality of Life 36-Item Short Form Health
Survey; PSA, prostate-specific antigen.
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the isoflavones group and the placebo group (Table 5).
There was no occurrence of severe adverse event in ei-
ther group during the study period. The nonserious
adverse events mainly included skin problems, followed
by gout, loss of libido, and generalized pain. No within-
groups or between-groups statistical difference of se-
rum PSA, testosterone levels, renal function, liver
function, and full blood count were found at the 12th
month.
Discussion
Pharmacological therapies including a-adrenergic blockers
and/or 5-a reductase inhibitors are the major medical treat-
ments for those who have moderate to severe LUTS/BPH.
However, evidence shows that both preparations have many
undesired effects.30 Therefore, many patients who suffer
from bothersome symptoms of LUS/ BPH but are worried
about the undesired effects of pharmacological therapies
Table 3. Within and Between Group Changes of IPSS and SF-36 at 6th and 12th Months
Placebo group Isoflavone group Between groups
Baseline
6th
month
12th
month P1 Baseline
6th
month
12th
month P1 P2 P3
Trend
P1
Trend
P2
Peak urine
flow rate
10.3 – 3.0 12.6 – 4.6 11.5 – 4.1 0.001 10.6 – 2.5 12.4 – 4.4 12.3 – 4.7 < 0.001 0.43 0.055 0.77 0.65
Residual
urine
volume
107.5– 77.5 78.1 – 69.2 67.6 – 54.6 < 0.001 126.0– 132.1 97.0 – 101.0 77.0 – 84.5 < 0.001 0.79 0.18 0.13 0.16
IPSS overall
scores
19.5 – 7.0 15.9 – 7.8 16.6 – 7.5 < 0.001 20.2 – 6.4 17.0 – 7.8 16.2 – 7.1 < 0.001 0.47 0.23 0.75 0.72
QOL SF-36
General
health
15.6 – 2.1 15.3 – 2.1 15.4 – 1.7 0.045 15.6 – 1.7 15.8 – 2.1 15.7 – 1.7 0.027 0.41 0.97 0.02 0.055
Mental
health
21.7 – 4.7 22.3 – 4.8 22.3 – 2.4 0.17 22.4 – 3.1 22.9 – 3.2 22.7 – 3.2 0.43 0.55 0.47 0.11 0.21
Baseline
6th
month
12th
month P Baseline
6th
month
12th
month P P’
PSA level 1.59 – 0.80 – 1.74 – 1.19 0.54 1.71 – 0.94 – 1.77 – 1.13 0.59 0.95
Testosterone
level
15.79– 6.38 – 16.23– 6.96 0.50 15.92– 5.01 – 15.62 – 4.97 0.30 0.31
P1, the change within groups from baseline to the 12th month; P2, the change between groups from the baseline to the 12th month; P3, the
change between groups from the 6th month to the 12th month; Trend P1, the change of trend between groups from baseline to the 12th
month; Trend P2, the change of trend between groups from the 6th month to the 12th month; IPSS, International Prostate Symptoms Scores;
QOL SF-36, Quality of Life 36-Item Short Form Health Survey; PSA, prostate-specific antigen.
FIG. 2. The change trend in peak urinary flow rate (Qmax)
of both intervention and control groups over 12 months. CI,
confidence interval.
FIG. 3. The change trend in postresidual urinary volume
(PVR) of both intervention and control groups over 12
months. CI, confidence interval.
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may turn to CAM as an alternative treatment. This patient-
centered approach is in line with the American Urologic
Association’s recommendation of ‘‘informed patient decision
making’’ as the standard for BPH management.21 This study
shows that isoflavones significantly improve the Qmax and
incomplete emptying in IPSS.
Qmax, PVR IPSS, and some of SF-36 scores significantly
improved between baseline and 1 year in both the inter-
vention and control groups. Nonetheless, only Qmax
( p = 0.055) and incomplete emptying subscore in IPSS
( p = 0.05) were marginally, respectively significantly differ-
ent between the two groups from 6 to 12 months, in addi-
tion to the general health domain of SF-36 from baseline to
12 months ( p = 0.02) and from 6 months to 12 months
( p = 0.055). Surprisingly, both groups improved in IPSS and
Qmax continually up to month 9, with an increase between
months 0 and 3, but both decreased between months 9 and
12. The unusual and unexpected strength of placebo effect
observed here needs further investigation. In other words,
both groups had similar and sustaining placebo effects up
to 9 months, but after that, apparently still existing symp-
toms overrode expectations. A study in 722 patients aged
50–80 years old with symptomatic BPH using doxazosin
showed a significant improvement in IPSS score (decreased
by 8.4 points from baseline) and Qmax (increase 2.2mL/sec
from baseline) ( p < 0.001) in the group using doxazosin.31
However, a significant improvement was also noted in the
placebo group; the IPSS decreased by 6.1 points from
baseline and Qmax increased 0.8mL/sec from baseline.31 It
would be also interesting to know whether the placebo ef-
fects in trials of BPH are exceptionally large, and whether
the placebo effects are larger with Chinese and other Asian
populations than with whites. However, phytotherapy has
many questions that remain unanswered concerning the
composition, extraction, and mechanism of action of these
compounds.
Since the dietary intake of soy food and one’s own per-
ception of taking an ‘‘actual’’ medication have strong asso-
ciations with the effectiveness of the intervention,
confounding biases may occur when imbalanced intake of
soy food between two groups takes place. Despite there was
no statistical difference occurring in soy intake between the
two groups, the possibility that effect differences might be
attributed to background or subconscious change of dietary
soy after entering into the trial cannot be ignored.
This trial has also successfully established the safety profile
in this group of patients with BPH and has set the foundation
for further longer-term studies on the combined effects of
conventional medicines and isoflavones or the role of iso-
flavones in the primary prevention of BPH, as suggested by
the BPH European Urology Guidelines.32 Conducting ran-
domized controlled trials on CAM faces challenges such as
dietary effect. Attempts have been made to minimize them by
the add-on dietary intake survey conducted among patients,
asking them to guess the group assignment as a way to assess
the dietary intake of soy food during the trial. Moreover,
while the conventional trials focus on the specific objective
outcomes of a symptom or disease, most CAM studies em-
phasize holistic recovery; hence the consistent improvements
in general health domain in quality of life seen in this study
may be more meaningful endpoints for this group of medi-
cations.
Conclusions
This double-blind pilot clinical study has successfully es-
tablished the safety of isoflavones. Similar improvement in
IPSS and Qmax was present in both the isoflavones and
placebo groups up to month 9, and subsequently there was
no more improvement in the verum group between months
9 and 12. As incomplete emptying and certain subscales of
SF-36 were slightly superior for isoflavones, which might
have a specific effect in this situation. These findings set the
foundation for further studies with isoflavones in BPH,
which should focus on possibly more favorable effects of
higher doses and better control of placebo effects.
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